Genesys Capital
Description
Genesys Capital is a prominent Canadian venture capital firm, exclusively dedicated to the life sciences sector. Established in 2000, it has grown to become one of the nation's largest and most active investors in healthcare and biotechnology. Headquartered in Toronto, Genesys Capital plays a crucial role in fostering innovation within Canada's burgeoning life sciences ecosystem, supporting companies from early development through to commercialization.
The firm's investment mandate is broad within life sciences, encompassing therapeutics, medical devices, diagnostics, and digital health solutions. Genesys Capital is stage-agnostic, demonstrating a willingness to invest across all phases of a company's growth, from seed-stage startups requiring initial capital to more mature, late-stage ventures seeking expansion funding. This flexible approach allows them to build diversified portfolios that capture opportunities across the entire healthcare value chain.
Genesys Capital typically deploys initial investments ranging from $2 million to $10 million. Beyond the initial cheque, the firm is committed to providing significant follow-on capital to support the continued growth and success of its portfolio companies, often participating in subsequent funding rounds. With over $300 million in committed capital under management across its four funds, Genesys Capital possesses substantial resources to back its investments and help promising life sciences companies achieve their strategic milestones and ultimately, bring innovative solutions to market.
Investor Profile
Genesys Capital has backed more than 28 startups, with 1 new investments in the last 12 months alone. The firm has led 4 rounds, about 14% of its total and boasts 8 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series A, Series B, Series C rounds (top funding stages).
- Majority of deals are located in Canada, United States.
- Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
- Led 1 rounds in the past year.
- Typical check size: $2M – $10M.
Stage Focus
- Series A (36%)
- Series B (32%)
- Series C (11%)
- Series Unknown (11%)
- Series F (4%)
- Series E (4%)
- Seed (4%)
Country Focus
- Canada (50%)
- United States (50%)
Industry Focus
- Biotechnology
- Health Care
- Pharmaceutical
- Medical
- Biopharma
- Therapeutics
- Oncology
- Medical Device
- Genetics
- Life Science
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
